Ignite Creation Date:
2024-05-05 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00279214
Status:
COMPLETED
Last Update Posted:
2009-09-02
First Post:
2005-12-15
Brief Title:
Hemodynamic and Perfusion Response to Drotrecogin Alfa Activated in Patients With Septic Shock
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
An Evaluation of Vasopressor Requirement Hemodynamic Response and Measures of Tissue Perfusion With the Administration of Drotrecogin Alfa Activated as Part of Physician-Directed Therapy in Patients With Septic Shock
Status:
COMPLETED
Status Verified Date:
2009-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will evaluate the vasopressor requirement hemodynamic response and measures of tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa activated compared to patients not receiving drotrecogin alfa activated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| F1K-US-EVDA | None | None | None |